Is a single 3 g oral dose of fosfomycin trometamol appropriate as first‑line treatment for an adult with uncomplicated Escherichia coli cystitis, provided the patient has no fosfomycin allergy, estimated glomerular filtration rate ≥30 mL/min/1.73 m², and low local resistance rates?

Fosfomycin for E. coli UTI

A single 3-gram oral dose of fosfomycin trometamol is appropriate as first-line treatment for uncomplicated E. coli cystitis in adults with eGFR ≥30 mL/min/1.73 m² and low local resistance rates, particularly when trimethoprim-sulfamethoxazole resistance exceeds 20%. 1, 2

Guideline-Based Recommendation

• Fosfomycin 3 g as a single oral dose is explicitly recommended by major guidelines (IDSA, EAU, AUA, ACP) as first-line therapy for uncomplicated cystitis in women, achieving approximately 91% clinical cure rates with therapeutic urinary concentrations maintained for 24–48 hours. 1, 2

• The single-dose regimen provides comparable clinical efficacy to 3-day trimethoprim-sulfamethoxazole or fluoroquinolones, despite slightly lower bacteriological eradication rates (78–83%), while offering superior convenience and minimal collateral damage to intestinal flora. 2

• Fosfomycin resistance remains exceptionally low at only 2.6% in initial E. coli infections and 5.7% at 9 months, making it highly reliable for empiric therapy. 2

When to Use Fosfomycin as First-Line

• Primary indication: When local E. coli resistance to trimethoprim-sulfamethoxazole exceeds 20%, fosfomycin becomes the preferred first-line agent alongside nitrofurantoin. 2

• Cost-effectiveness threshold: Fosfomycin becomes economically favorable when trimethoprim resistance exceeds 30–35% in the community. 2

• Patient preference scenarios: The single-dose convenience significantly improves adherence compared to 3–7 day regimens, making it ideal for patients with adherence concerns. 2

Pharmacodynamic Support

• Bactericidal activity is rapid and sustained: Fosfomycin achieves peak urinary concentrations of ~4000 mg/L with complete bacterial eradication as early as 1 hour after dosing, maintained over 48 hours against E. coli including ESBL-producing and carbapenemase-producing strains. 3, 4

• The urinary concentrations remain >100 µg/mL for 48 hours, providing a pharmacodynamic advantage (ƒT>MIC of 100%) that explains the high microbiological cure rates despite single-dose administration. 3, 4

Critical Contraindications

• Do NOT use fosfomycin for pyelonephritis or upper urinary tract infections due to insufficient tissue penetration and lack of efficacy data; oral fosfomycin is restricted to uncomplicated lower UTI (cystitis) only. 1, 2

• Do NOT use in men with UTIs: The European Association of Urology explicitly recommends against fosfomycin for routine use in men due to limited clinical efficacy data in this population. 2, 5

• Renal function requirement: Safe to use with eGFR ≥30 mL/min/1.73 m² without dose adjustment; avoid in severe renal impairment (eGFR <30). 2

Safety Profile

• Minimal adverse effects: Diarrhea, nausea, and vomiting are the most common side effects, occurring in 5.6–28% of patients, with no serious drug-related adverse events reported in clinical trials. 2

• Electrolyte monitoring: Can cause hypokalemia, hypocalcemia, hypomagnesemia, and hypernatremia; monitor electrolytes in patients with pre-existing renal dysfunction or cardiac insufficiency. 2

• Pregnancy safety: Fosfomycin is safe in pregnancy and recommended for asymptomatic bacteriuria in pregnant women as standard short-course treatment or single-dose administration. 2

Treatment Failure Management

• If symptoms persist after 2–3 days or recur within 2 weeks: Obtain urine culture and susceptibility testing immediately, then switch to a different antibiotic class (nitrofurantoin 100 mg BID for 5 days or TMP-SMX 160/800 mg BID for 3 days if susceptible) for a full 7-day course. 1, 2

• Do NOT repeat the single-dose fosfomycin regimen for treatment failures; assume resistance and select an alternative agent based on culture results. 2

Comparison with Other First-Line Agents

• Nitrofurantoin (100 mg BID × 5 days): Achieves 93% clinical cure and 88% microbiological eradication but requires 5 days of dosing; contraindicated when eGFR <30 mL/min/1.73 m². 2

• Trimethoprim-sulfamethoxazole (160/800 mg BID × 3 days): Provides 93% clinical cure and 94% microbiological eradication but should only be used when local E. coli resistance is <20% and patient has not received TMP-SMX in prior 3 months. 2

• Fluoroquinolones: Should be reserved exclusively for culture-proven resistant pathogens or documented failure of first-line therapy due to serious adverse effects (tendon rupture, peripheral neuropathy) and rising global resistance. 2

Clinical Decision Algorithm

1. Confirm uncomplicated cystitis (no fever >38°C, flank pain, pregnancy, catheter, or immunosuppression). 2

2. Assess local TMP-SMX resistance:

   • If <20% and no recent TMP-SMX use → TMP-SMX 160/800 mg BID × 3 days 2
   • If ≥20% or unknown → Fosfomycin 3 g single dose or nitrofurantoin 100 mg BID × 5 days 2

3. Administer fosfomycin on empty stomach mixed with 90–120 mL water; do not repeat the dose. 2

4. No routine urine culture required for typical uncomplicated cystitis in otherwise healthy women. 2

5. Obtain culture only if: symptoms persist after therapy, recur within 2–4 weeks, fever/flank pain develops, or atypical presentation. 2

Key Pitfalls to Avoid

• Do not use for suspected pyelonephritis even if patient has normal renal function; switch to fluoroquinolone or parenteral cephalosporin for upper tract involvement. 1, 2

• Do not treat asymptomatic bacteriuria except in pregnant women or before urological procedures breaching the mucosa. 2

• Do not use empirically in men with UTIs; male UTIs are considered complicated and require culture-directed therapy with longer duration (7–14 days). 5

• Verify low local resistance rates before using as first-line; although global resistance is low (2.6%), regional variations exist. 2, 6